- Home
- MGIC vs CMMB Comparison
MGIC vs CMMB Comparison
Compare MGIC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- CMMB
- Stock Information
- Founded
- MGIC 1983
- CMMB 2004
- Country
- MGIC Israel
- CMMB Israel
- Employees
- MGIC N/A
- CMMB N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- CMMB Health Care
- Exchange
- MGIC Nasdaq
- CMMB Nasdaq
- Market Cap
- MGIC 990.3M
- CMMB 22.0M
- IPO Year
- MGIC 1991
- CMMB N/A
- Fundamental
- Price
- MGIC $19.81
- CMMB $2.63
- Analyst Decision
- MGIC Buy
- CMMB Strong Buy
- Analyst Count
- MGIC 2
- CMMB 2
- Target Price
- MGIC $18.00
- CMMB $26.50
- AVG Volume (30 Days)
- MGIC 41.2K
- CMMB 155.4K
- Earning Date
- MGIC 11-17-2025
- CMMB 11-13-2025
- Dividend Yield
- MGIC 2.84%
- CMMB N/A
- EPS Growth
- MGIC 16.93
- CMMB N/A
- EPS
- MGIC 0.78
- CMMB N/A
- Revenue
- MGIC $584,528,000.00
- CMMB N/A
- Revenue This Year
- MGIC $11.72
- CMMB N/A
- Revenue Next Year
- MGIC $6.24
- CMMB N/A
- P/E Ratio
- MGIC $24.76
- CMMB N/A
- Revenue Growth
- MGIC 11.98
- CMMB N/A
- 52 Week Low
- MGIC $10.42
- CMMB $2.59
- 52 Week High
- MGIC $22.00
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- MGIC 47.41
- CMMB 18.39
- Support Level
- MGIC $19.23
- CMMB $2.70
- Resistance Level
- MGIC $20.80
- CMMB $3.09
- Average True Range (ATR)
- MGIC 0.50
- CMMB 0.17
- MACD
- MGIC -0.03
- CMMB -0.02
- Stochastic Oscillator
- MGIC 51.17
- CMMB 5.88
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.